Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, takes note of the market reaction to the evolution of the Company's share price, but wants to reaffirm its strategic intentions concerning its product-candidate Donesta.

The Company is therefore maintaining the operational calendar as announced on September 23rd at the half-year 2022 results.

Negotiations with potential partners to commercialize, the product-candidate, Donesta are ongoing. The objective of announcing binding offers at the end of the year is maintained. The receipt of the first safety data from the Donesta Phase 3 Study conducted in the United States and Canada is also expected by the end of 2022.

Contact:

Tel: +32 (0)4 349 28 22

Email: info@mithra.com

(C) 2022 Electronic News Publishing, source ENP Newswire